Advertisement

Disparities in clinical trial participation among older adults with multiple myeloma in the United States

  • Author Footnotes
    1 PW and AC contributed equally to this manuscript.
    Priscila White
    Footnotes
    1 PW and AC contributed equally to this manuscript.
    Affiliations
    Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America

    Institute for Cancer Outcomes and Survivorship, Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, United States of America
    Search for articles by this author
  • Author Footnotes
    1 PW and AC contributed equally to this manuscript.
    Abigail Cooley
    Footnotes
    1 PW and AC contributed equally to this manuscript.
    Affiliations
    Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America

    Institute for Cancer Outcomes and Survivorship, Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, United States of America
    Search for articles by this author
  • Susan Bal
    Affiliations
    Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, United States of America
    Search for articles by this author
  • Kelly Godby
    Affiliations
    Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, United States of America
    Search for articles by this author
  • Gayathri Ravi
    Affiliations
    Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, United States of America
    Search for articles by this author
  • Deanna Clark
    Affiliations
    Institute for Cancer Outcomes and Survivorship, Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, United States of America
    Search for articles by this author
  • Clare Ubersax
    Affiliations
    Institute for Cancer Outcomes and Survivorship, Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, United States of America
    Search for articles by this author
  • Grant R. Williams
    Affiliations
    Institute for Cancer Outcomes and Survivorship, Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, United States of America

    Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, United States of America
    Search for articles by this author
  • Luciano J. Costa
    Affiliations
    Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, United States of America
    Search for articles by this author
  • Smith Giri
    Correspondence
    Corresponding author at: Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, United States of America.
    Affiliations
    Institute for Cancer Outcomes and Survivorship, Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, United States of America

    Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, United States of America
    Search for articles by this author
  • Author Footnotes
    1 PW and AC contributed equally to this manuscript.
      Multiple myeloma (MM) is the second most common hematologic malignancy in the US with a median age at diagnosis of 70 years, and more than two-thirds of patients being over the age of 65. It is also more frequent in men, and two to three times more frequent in Black patients than in White patients [
      • Institute, N.C
      SEER Cancer Stat Facts: Myeloma.
      ]. Although tremendous advancements in treatment of this disease has been made in the last two decades, treatment of older adults with MM remains a challenge and this population has not seen similar gains of survival compared to younger patients [
      • Costa L.J.
      • et al.
      Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Geriatric Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Institute, N.C
        SEER Cancer Stat Facts: Myeloma.
        (Available from:)
        • Costa L.J.
        • et al.
        Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States.
        Blood Adv. 2017; 1: 282-287
        • Hariton E.
        • Locascio J.J.
        Randomised controlled trials - the gold standard for effectiveness research.
        BJOG. 2018; 125: 1716
        • Costa L.J.
        • Hari P.N.
        • Kumar S.K.
        Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity.
        Leuk Lymphoma. 2016; 57: 2827-2832
        • Kanapuru B.
        • et al.
        Enrollment of older adults in clinical trials evaluating patients with hematologic malignancies - the Food and Drug Administration (FDA) experience.
        Blood. 2017; 130: 861
        • Singh H.
        • et al.
        FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: a 10-year experience by the U.S. Food and Drug Administration.
        J Clin Oncol. 2017; 35: 10009
        • Rajkumar S.V.
        • Richardson P.
        • San Miguel J.F.
        Guidelines for determination of the number of prior lines of therapy in multiple myeloma.
        Blood. 2015; 126: 921-922
        • Fonseca R.
        • et al.
        Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma.
        BMC Cancer. 2020; 20: 1087
        • Giri S.
        • et al.
        Real-world applicability of commercial chimeric antigen receptor T-cell therapy among older adults with relapsed and/or refractory multiple myeloma.
        Am J Hematol. 2022 Apr; 97: E153-E155
        • Clopper C.J.
        • Pearson E.S.
        The use of confidence or fiducial limits illustrated in the case of the binomial.
        Biometrika. 1934; 26: 404-413
        • Murthy V.H.
        • Krumholz H.M.
        • Gross C.P.
        Participation in cancer clinical trials: race-, sex-, and age-based disparities.
        Jama. 2004; 291: 2720-2726
        • National Cancer Institute Surveillance Epidemiology and End Results Program
        Cancer Stat Facts: Cancer of Any Site.
        (Available from:)
        • Bhatnagar V.
        • et al.
        FDA analysis of racial demographics in multiple myeloma trials.
        Blood. 2017; 130: 4352
        • US Food and Drug Administration
        Enhancing the Diversity of Clinical Trial Populations: Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry.
        (Available from:)
        • Sedrak M.S.
        • et al.
        Older adult participation in cancer clinical trials: a systematic review of barriers and interventions.
        CA Cancer J Clin. 2021; 71: 78-92